Henrik Hjorth-Hansen
+4773598673
+4797121240
+4772825176
Gastrosenteret, Øya
About
Hematologist. Research focus area Chronic Myeloid Leukemia . Chairman Nordic CML Study group (NCMLSG)
Publications
2025
-
Nygrén, Petra;
Bouhlal, Jonas;
Jokinen, Emmi;
Forstén, Sofia;
Laajala, Essi;
Dias, Diogo.
(2025)
High-throughput drug screening identifies SMAC mimetics as enhancers of NK-cell cytotoxicity in chronic myeloid leukemia.
Blood
Academic article
2024
-
Flygt, Hjalmar;
Söderlund, Stina;
Richter, Johan;
Saussele, Susanne;
Koskenvesa, Perttu;
Stenke, Leif.
(2024)
Correction to: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial (Leukemia, (2024), 10.1038/s41375-024-02145-6).
Leukemia
Errata
-
Warfvinge, Rebecca;
Geironson Ulfsson, Linda;
Dhapola, Parashar;
Safi, Fatemeh;
Sommarin, Mikael;
Soneji, Shamit.
(2024)
Single-cell multiomics analysis of chronic myeloid leukemia links cellular heterogeneity to therapy response.
eLIFE
Academic article
-
Mahon, Francois-Xavier;
Pfirrmann, Markus;
Dulucq, Stéphanie;
Hochhaus, Andreas;
Panayiotidis, Panayiotis;
Almeida, Antonio.
(2024)
European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission.
Journal of Clinical Oncology
Academic article
-
Gambacorti-Passerini, Carlo;
Brümmendorf, Tim H.;
Abruzzese, Elisabetta;
Kelly, Kevin R.;
Oehler, Vivian G.;
García-Gutiérrez, Valentín.
(2024)
Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trial.
Leukemia
Academic article
-
Efficace, Fabio;
Mahon, Francois-Xavier;
Richter, Johan;
Piciocchi, Alfonso;
Cipriani, Marta;
Nicolini, Franck E..
(2024)
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial.
Leukemia
Academic article
-
Flygt, Hjalmar;
Söderlund, Stina;
Richter, Johan;
Saussele, Susanne;
Koskenvesa, Perttu;
Stenke, Leif.
(2024)
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial.
Leukemia
Academic article
2023
-
Machova Polakova, Katerina;
Albeer, Ali;
Polivkova, Vaclava;
Krutska, Monika;
Vlcanova, Katerina;
Curik, Nikola.
(2023)
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib.
Leukemia
Academic article
-
Huuhtanen, Jani;
Adnan-Awad, Shady;
Theodoropoulos, Jason;
Forstén, Sofia;
Warfvinge, Rebecca;
Dufva, Olli.
(2023)
Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation.
Leukemia
Academic article
-
Geelen, Inge G.P.;
Gullaksen, Stein-Erik;
Ilander, Mette M.;
Olssen-Strömberg, Ulla;
Mustjoki, Satu;
Richter, Johan.
(2023)
Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects.
Annals of Hematology
Academic article
-
Behsen, Alenka Djarmila;
Vandsemb, Esten Nymoen;
Slørdahl, Tobias Schmidt;
Hjorth-Hansen, Henrik;
Quist-Paulsen, Petter;
Misund, Kristine.
(2023)
A patient with minimal myeloma treatment who survived for 20 years.
Haematologica
Academic article
2022
-
Huuhtanen, Jani;
Ilander, Mette;
Yadav, Bhagwan;
Dufva, Olli M.J.;
Lähteenmäki, Hanna;
Kasanen, Tiina.
(2022)
IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia.
Journal of Clinical Investigation
Academic article
2021
-
Flygt, Hjalmar;
Söderlund, Stina;
Stentoft, Jesper;
Richter, Johan;
Koskenvesa, Perttu;
Mustjoki, Satu.
(2021)
Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study.
European Journal of Haematology
Academic article
-
Richter, Johan;
Lübking, Anna;
Söderlund, Stina;
Lotfi, Kourosh;
Markevärn, Berit;
Själander, Anders.
(2021)
Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR—final report from AFTER-SKI.
Leukemia
Academic article
2020
-
Hochhaus, Andreas;
Baccarani, Michele;
Silver, Richard T.;
Schiffer, Charles A.;
Apperley, Jane F.;
Cervantes, Francisco.
(2020)
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.
Leukemia
Academic literature review
-
Söderlund, Stina;
Persson, Inger;
Ilander, Mette;
Guilhot, Joelle;
Hjorth-Hansen, Henrik;
Koskenvesa, Perttu.
(2020)
Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy.
Leukemia Research
Academic article
-
Berentsen, Sigbjørn;
Barcellini, Wilma;
D'Sa, Shirley;
Randen, Ulla;
Tvedt, Tor Henrik Anderson;
Fattizzo, Bruno.
(2020)
Cold agglutinin disease revisited: a multinational, observational study of 232 patients.
Blood
Academic article
-
Rio-Machin, Ana;
Villiamy, Tom;
Hug, Nele;
Walne, Amanda;
Tawana, Kiran;
Cardoso, Shirleny.
(2020)
The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants.
Nature Communications
Academic article
2019
-
Kreutzman, Anna;
Yadav, Bhagwan;
Brümmendorf, Tim H.;
Gjertsen, Bjørn Tore;
Lee, Moon Hee;
Janssen, Jeroen.
(2019)
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line.
Oncoimmunology
Academic article
-
Hjorth-Hansen, Henrik.
(2019)
TKI safety.
HemaSphere
Academic article
2018
-
Bouillon, Anne-Sophie;
Ventura Ferreira, Monica S.;
Awad, Shady Adnan;
Richter, Johan;
Hochhaus, Andreas;
Kunzmann, Volker.
(2018)
Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemia.
Blood Advances
Academic article
-
Landberg, Niklas;
von Palffy, Sophia;
Askmyr, Maria K.;
Lilljebjorn, Henrik;
Sanden, Carl;
Rissler, Marianne.
(2018)
CD36 Defines Primitive Chronic Myeloid Leukemia Cells Less Responsive To Imatinib But Vulnerable To Antibody-Based Therapeutic Targeting.
Haematologica
Academic article
-
Saussele, Susanne;
Richter, Johan;
Guilhot, Joelle;
Gruber, Franz;
Hjorth-Hansen, Henrik;
Almeida, Antonio.
(2018)
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
The Lancet Oncology
Academic article
2017
-
Pietarinen, Paavo O;
Eide, Christopher A;
Ayuda-Duran, Maria del Pilar;
Potdar, Swapnil;
Kuusanmäki, Heikki;
Andersson, Emma I.
(2017)
Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
OncoTarget
Academic article
-
Gullaksen, Stein-Erik;
Skavland, Jørn;
Gavasso, Sonia;
Tosevski, Vinko;
Warzocha, Krzysztof;
Dumrese, Claudia.
(2017)
Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib.
Haematologica
Academic article
-
Ilander, Mette;
Olsson-Strömberg, Ulla;
Schlums, Heinrich;
Guilhot, Joëlle;
Brück, Oscar;
Lähteenmäki, Hanna.
(2017)
Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.
Leukemia
Academic article
-
Hochhaus, Andreas;
Saussele, Susanne;
Rosti, Gianantonio;
Mahon, François-Xavier;
Janssen, Jeroen J.W.M.;
Hjorth-Hansen, Henrik.
(2017)
Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Annals of Oncology
Academic article
-
Warfvinge, Rebecca;
Geironson, Linda;
Sommarin, Mikael NE;
Lang, Stefan;
Karlsson, Christine;
Roschupkina, Teona.
(2017)
Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML.
Blood
Academic article
-
Rajala, Hanna L.M.;
El Missiry, Mohamed;
Ruusila, Anniina;
Koskenvesa, Perttu;
Brümmendorf, Tim H.;
Gjertsen, Bjørn Tore.
(2017)
Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia.
Journal of Cancer Research and Clinical Oncology
Academic article
-
Müller, Martin C.;
Cervantes, Francisco;
Hjorth-Hansen, Henrik;
Janssen, Jeroen J.W.M.;
Milojkovic, Dragana;
Rea, Delphine.
(2017)
Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel.
Critical Reviews in Oncology/Hematology
Academic literature review
-
El Missiry, Mohamed;
Hjorth-Hansen, Henrik;
Richter, Johan;
Olson-Strömberg, Ulla;
Stenke, Leif;
Porkka, Kimmo.
(2017)
Early BCR-ABL1 transcript decline after 1 month of tyrosine kinase inhibitor therapy as an indicator for treatment response in chronic myeloid leukemia.
PLOS ONE
Academic article
2016
-
Hjorth-Hansen, Henrik;
Stentoft, Jesper;
Richter, Johan;
Koskenvesa, Perttu;
Höglund, Martin;
Dreimane, Arta.
(2016)
Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients.
Leukemia
Academic article
-
Landberg, Niklas;
Hansen, Nils Jakob Vest;
Askmyr, Maria K.;
Ågerstam, Helena;
Lassen, Carin F.;
Rissler, Marianne.
(2016)
IL1RAP expression as a measure of leukemic stem cell burden at diagnosis of chronic myeloid leukemia predicts therapy outcome.
Leukemia
Letter to the editor
-
El Missiry, Mohamed;
Adnan Awad, Shady;
Rajala, Hanna L.;
Al-Samadi, Ahmed;
Ekblom, Marja;
Markevän, Berit.
(2016)
Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia.
Journal of Cancer Research and Clinical Oncology
Academic article
-
Stray-Pedersen, Asbjørg;
Sorte, Hanne Sørmo;
Samarakoon, Pubudu Saneth;
Gambin, Tomasz;
Chinn, Ivan K.;
Akdemir, Zeynep H.C..
(2016)
Primary immunodeficiency diseases: Genomic approaches delineate heterogeneous Mendelian disorders.
Journal of Allergy and Clinical Immunology
Academic article
-
Söderlund, Stina;
Christiansson, Lisa;
Persson, Inger;
Hjorth-Hansen, Henrik;
Richter, Johan;
Simonsson, Bengt.
(2016)
Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli.
Leukemia Research
Academic article
2015
-
Christiansson, Lisa;
Söderlund, Stina;
Mangsbo, Sara;
Hjorth-Hansen, Henrik;
Höglund, Martin;
Markevärn, Berit.
(2015)
The tyrosine kinase inhibitors imatinib and dasatinib reduce myeloid suppressor cells and release effector lymphocyte responses.
Molecular Cancer Therapeutics
Academic literature review
-
Espinosa, Aurora;
Hjorth-Hansen, Henrik;
Aasly, Karin;
Teigum, Ingvild;
Sivertsen, Guro Hustad;
Seghatchian, Jerard.
(2015)
Implementation of a standardised method for the production of allogeneic serum eye drops from regular blood donors in a Norwegian University Hospital: Some methodological aspects and clinical considerations.
Transfusion and Apheresis Science
Academic literature review
-
Hjorth-Hansen, Henrik;
Stenke, Leif;
Söderlund, Stina;
Dreimane, Arta;
Ehrencrona, Hans;
Gedde-Dahl, Thobias.
(2015)
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: Clinical results from a randomised phase-2 study (NordCML006).
European Journal of Haematology
Academic article
2014
-
Koskenvesa, P;
Kreutzman, Anna;
Rohon, P;
Pihlman, M;
Vakkila, Emmi;
Rasanen, Anu.
(2014)
Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response.
European Journal of Haematology
Academic article
2013
-
Fossmark, Reidar;
Skarsvåg, Espen Christoffer;
Aarset, Harald;
Hjort-Hansen, Henrik;
Waldum, Helge.
(2013)
Symptomatic primary (Al) amyloidosis of the stomach and duodenum.
Case Reports in Gastrointestinal Medicine
Academic article
-
Skarsvåg, Espen Christoffer;
Hjort-Hansen, Henrik;
Fossmark, Reidar.
(2013)
Symptomatic primary (AL) amyloidosis in the stomach and duodenum.
BestPractice Gastroenterologi
Article in business/trade/industry journal
-
Baccarani, Michele;
Deininger, MW;
Rosti, Gianantonio;
Hochhaus, Andreas;
Soverini, Simona;
Apperley, J.F..
(2013)
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
Blood
Academic literature review
-
Hjort-Hansen, Henrik;
Abboud, Camille;
Abdel-Rahman, Fawzi;
Abruzzese, Elizabetta;
Aguayo, Alvaro;
Aljurf, Mahmoud Deeb Saeed.
(2013)
Price of drugs for chronic myeloid leukemia (CML), reflection of the unsustainable cancer drug prices: perspective of CML Experts.
Blood
Academic literature review
-
Mustjoki, Satu;
Richter, Johan;
Barbany, Gisela;
Ehrencrona, Hans;
Fioretos, Thoas;
Gedde-Dahl, Thobias.
(2013)
Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients.
Leukemia
Academic article
2012
-
Jönsson, Sofia;
Hjorth-Hansen, Henrik;
Olsson, Bob;
Wadenvik, H;
Sundan, Anders;
Standal, Therese.
(2012)
Imatinib inhibits proliferation of human mesenchymal stem cells and promotes early but not late osteoblast differentiation in vitro.
Journal of Bone and Mineral Metabolism
Academic article
-
Gruber, Franz;
Lundan, Tuija;
Goll, Rasmus;
Silye, Aleksandra;
Mikkola, Ingvild;
Rekvig, Ole Petter.
(2012)
BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations?.
Medical Oncology (MO)
Academic article
-
Kreutzman, Anna;
Jaatinen, Taina;
Greco, D;
Vakkila, Emmi;
Richter, J;
Ekblom, Marja.
(2012)
Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia.
Experimental Hematology
Academic article
2011
-
Simonsson, B;
Gedde-Dahl, Tobias;
Markevärn, B;
Remes, Kari;
Stentoft, Jesper;
Almqvist, Anders.
(2011)
Combination of pegylated IFN-alpha 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia.
Blood
Academic article
-
Simonsson, B;
Hjorth-Hansen, Henrik;
Bjerrum, Ole W;
Porkka, K.
(2011)
Interferon alpha for Treatment of Chronic Myeloid Leukemia.
Current Drug Targets
Academic literature review
-
Koskela, Hanna;
Strømberg, Anniina;
Richter, Johan;
Hjorth-Hansen, Henrik;
Porkka, Kimmo;
Mustjoki, Satu.
(2011)
Tyrosine Kinase Inhibitor Therapy Induced Changes in Humoral Immunity in Patients with Chronic Myeloid Leukemia.
Blood
Abstract
2010
-
Jönsson, S;
Hjorth-Hansen, Henrik;
Olsson, B;
Wadenvik, H;
Sundan, Anders;
Standal, Therese.
(2010)
Second-generation TKI dasatinib inhibits proliferation of mesenchymal stem cells and osteoblast differentiation in vitro.
Leukemia
Reader opinion piece
-
Gimsing, Peter;
Carlson, Kristina;
Turesson, Ingemar;
Fayers, Peter;
Waage, Anders;
Vangsted, Annette.
(2010)
Effect of pamidronate 30mg versus 90mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial.
The Lancet Oncology
Academic article
-
Berentsen, Sigbjørn;
Randen, Ulla;
Vågan, Anna Marita;
Hjort-Hansen, Henrik;
Vik, Anders;
Dalgaard, Jakob.
(2010)
High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease.
Blood
Academic article
-
Simonsson, Bengt;
Gedde-Dahl, Thobias;
Markevärn, Berit;
Remes, Kari;
Stentoft, Jesper;
Almqvist, Anders.
(2010)
MAJOR MOLECULAR RESPONSE RATE AT ONE YEAR IS HIGHER IF PEGYLATED INTERFERON ALPHA-2B IS ADDED TO IMATINIB IN NON-HR CHRONIC MYELOID LEUKEMIA PATIENTS IN IMATINIB INDUCED COMPLETE HEMATOLOGICAL REMISSION.
Haematologica
Abstract
2009
-
Reseland, Janne Elin;
Reppe, Sjur;
Olstad, Ole Kristoffer;
Hjorth-Hansen, Henrik;
Brenne, Anne-Tove;
Syversen, Unni.
(2009)
Abnormal adipokine levels and leptin-induced changes in gene expression profiles in multiple myeloma.
European Journal of Haematology
Academic article
-
Mustjoki, Satu;
Ekblom, M;
Arstila, TP;
Dybedal, I;
Epling-Burnette, PK;
Guilhot, F.
(2009)
Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy.
Leukemia
Academic article
-
Baccarani, Michele;
Rosti, Gianantonio;
Castagnetti, Fausto;
Haznedaroglu, Ibrahim;
Porkka, Kimmo;
Abruzzese, Elisabetta.
(2009)
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study.
Blood
Academic article
-
Hjorth-Hansen, Henrik;
Gruber, Franz.
(2009)
Towards a quantitative understanding of CML resistance – selective and de-selective processes upon treatment with tyrosine kinase inhibitors and their clinical interpretation.
Franz Gruber selv
Doctoral dissertation
-
Vefring, HK;
Gruber, Franz;
Wee, L;
Hovland, R;
Hjorth-Hansen, H;
Dahl, TG.
(2009)
Chronic Myelogenous Leukemia with the e6a2 BCR-ABL and Lacking Imatinib Response: Presentation of Two Cases.
Acta Haematologica
Academic article
-
Simonsson, Bengt;
Gedde-Dahl, Thobias;
Markevarn, B;
Remes, Kari;
Stentoft, J;
Almqvist, Anders.
(2009)
A Randomized Phase II Study Comparing Imatinib and the Combination of Imatinib and Pegylated Interferon Alpha-2b in Newly Diagnosed Non-High Risk Chronic Myeloid Leukemia (CML) Patients in Complete Hematological Remission After Imatinib Induction Therapy.
Blood
Abstract
2008
-
Porkka, Kimmo;
Koskenvesa, Perttu;
Lundan, Tuija;
Rimpilaeinen, Johanna;
Mustjoki, Satu;
Smykla, Richard.
(2008)
Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia.
Blood
Academic article
2007
-
Koskenvesa, P;
Rimpilainen, J;
Lundan, T;
Mustjoki, S;
Brethon, B;
Hjorth-Hansen, H.
(2007)
Dasatinib is an effective treatment of central nervous system Ph-positive leukemia.
Haematologica
Abstract
2006
-
Gruber, Franz;
Hjorth-Hansen, H;
Mikkola, ingvild;
Stenke, L;
Johansen, Terje.
(2006)
A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib.
Leukemia
Reader opinion piece
-
Vanky, Eszter;
Hjorth-Hansen, Henrik;
Carlsen, Sven Magnus.
(2006)
Metformin and early pregnancy?.
Fertility and Sterility
Reader opinion piece
-
Vanky, Eszter;
Salvesen, Kjell Å;
Hjorth-Hansen, Henrik;
Bjerve, Kristian S;
Carlsen, Sven Magnus.
(2006)
Beneficial effect of metformin on pregnancy outcome in women with polycystic ovary syndrome is not associated with major changes in C-reactive protein levels or indices of coagulation.
Fertility and Sterility
Academic article
-
Berentsen, Sigbjørn;
Ulvestad, Tore Elling;
Ulvestad, Elling;
Langholm, Ruth;
Beiske, Klaus;
Hjorth-Hansen, Henrik.
(2006)
Primary chronic cold agglutinin disease: a population based clinical study of 86 patients.
Studies in Surface Science and Catalysis
Academic article
2005
-
Rosti, Gianantonio;
Martinelli, G;
Castagnetti, F;
Testoni, N;
Specchia, G;
Bassan, R.
(2005)
Imatinib 800 mg: Preliminary results of a phase II trial of the GIMEMA CML working party in intermediate sokal risk patients and status-of-the-art of an ongoing multinational, prospective randomized trial of imatinib standard dose (400 mg daily) vs high dose (800 mg daily) in high sokal risk patients.
Blood
Abstract
-
Gruber, Franz;
Lamark, T;
Aanonli, T;
Sovershaev, MA;
Olsen, Marita;
Gedde-dahl, Tobias.
(2005)
Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL.
Leukemia
Academic article
-
Gruber, Franz;
Lamark, Trond;
Ånonli, Aileeen Cathrine;
Sovershaev, Mikhail;
Olsen, M;
Gedde-Dahl, T.
(2005)
Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL.
Leukemia
Academic article
2004
-
Hov, Håkon;
Holt, Randi Utne;
Rø, Torstein Baade;
Fagerli, Unn-Merete;
Hjort-Hansen, Henrik;
Baykov, Vadim.
(2004)
A Selective c-Met Inhibitor Blocks an Autocrine Hepatocyte Growth Factor Growth Loop in ANBL-6 Cells and Prevents Migration and Adhesion of Myeloma cells.
Clinical Cancer Research
Academic article
-
Holt, Randi Utne;
Hjorth-Hansen, Henrik;
Waage, Anders;
Hjertner, ¯yvind;
Sundan, Anders;
Børset, Magne.
(2004)
Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells.
Oncogene
Academic article
-
Hov, Håkon;
Holt, Randi Utne;
Rø, Torstein;
Fagerli, Unn-merete;
Hjorth-Hansen, Henrik;
Baykov, Vadim.
(2004)
A selective c-Met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells.
Clinical Cancer Research
Academic article
-
Standal, T;
Hjort-Hansen, H;
Rasmussen, T;
Dahl, Inger Marie;
Lenhoff, S;
Brenne, AT.
(2004)
Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma.
Haematologica
Academic article
-
Berentsen, Sigbjørn;
Ulvestad, Elling;
Gjertsen, Bjørn tore;
Hjorth-Hansen, Henrik;
Langholm, Ruth;
Ghanima, Waleed.
(2004)
Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients.
Blood
Academic article
-
Berentsen, S;
Ulvestad, E;
Gjertsen, BT;
Hjort-Hansen, H;
Langholm, R;
Knutsen, H.
(2004)
Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients.
Blood
Academic article
-
Standal, T;
Hjorth-Hansen, Henrik;
Rasmussen, T;
Dahl, Inger Marie S.;
Lenhoff, Stig;
Brenne, Anne Tove.
(2004)
Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma.
Haematologica
Academic article
-
Hjorth-Hansen, Henrik;
Gruber, Franz;
Gedde-dahl, Tobias.
(2004)
Nasjonalt handlingsprogram for kronisk myelogen leukemi.
Norsk selskap for hematologi
Report
2002
-
Brenne, Anne Tove;
Rø, Torstein Baade;
Waage, Anders;
Sundan, Anders;
Børset, Magne;
Hjorth-Hansen, Henrik.
(2002)
Interleukin-21 is a growth and survival factor for human myeloma cells.
Blood
Academic article
2001
-
Hjorth-Hansen, Henrik.
(2001)
Sulter ut kreften med nye medisiner.
Dagbladet
Feature article
-
Seidel, Carina;
Hjertner, ¯yvind;
Abildgaard, Niels;
Heikendorff, Lene;
Hjorth, M.;
Westin, Jan.
(2001)
Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease.
Blood
Academic article
-
Hjertner, ¯yvind;
Hjorth-Hansen, Henrik;
Børset, Magne;
Seidel, Carina;
Waage, Anders;
Sundan, Anders.
(2001)
Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells.
Blood
Academic article
-
Hjorth-Hansen, Henrik.
(2001)
Novel cytokines in growth control and bone disease of multiple myeloma.
NTNU Trykk
Doctoral dissertation
2000
-
Hjertner, ¯yvind;
Qvigstad, Gunnar;
Hjorth-Hansen, Henrik;
Seidel, Carina;
Woodliff, Jeffery;
Epstein, Joshua.
(2000)
Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells.
British Journal of Haematology
Academic article
-
Seidel, Carina;
Børset, Magne;
Hjertner, ¯yvind;
Cao, Dianjun;
Abildgaard, Niels;
Hjorth-Hansen, Henrik.
(2000)
High levels of soluble syndecan-1 in myeloma-derived bone marrow : modulation of hepatocyte growth factor activity.
Blood
Academic article
1999
-
Hjorth-Hansen, Henrik;
Seidel, Carina;
Lamvik, Jon;
Børset, Magne;
Sundan, Anders;
Waage, Anders.
(1999)
Elevated serum concentrations of hepatocyte growth factor in acute myelocytic leukaemia.
European Journal of Haematology
Academic article
-
Børset, Magne;
Hjort-Hansen, Henrik;
Johnsen, Ann-Charlotte;
Seidel, Carina;
Waage, Anders;
Espevik, Terje.
(1999)
Apoptosis, proliferation and NF-k(kappa)B activation induced by agonistic Fas antibodies in the human myeloma cell line OH-2: amplification of Fas-mediated apoptosis by tumor necrosis factor.
European Journal of Haematology
Academic article
-
Hjertner, ¯yvind;
Torgersen, Maria Lyngaas;
Seidel, Carina;
Hjort-Hansen, Henrik;
Waage, Anders;
Børset, Magne.
(1999)
Hepatocyte Growth Factor (HGF) Induces Interleukin-11 Sedretion From Osteoblasts: A Possible Role for HGF in Myeloma-Associated Osteolytic Bone Disease.
Blood
Academic article
-
Børset, Magne;
Seidel, Carina;
Hjorth-Hansen, Henrik;
Waage, Anders;
Sundan, Anders.
(1999)
The Role of Hepatocyte Growth Factor and its Receptor C-Met in Multiple Myeloma and Other Blood Malignancies.
Leukemia and Lymphoma
Academic article
-
Hjort-Hansen, Henrik;
Waage, Anders;
Børset, M..
(1999)
Interleukin-15 blocks apoptosis and induces proliferation of the human myeloma cell line OH-2 and freshly isolated myeloma cells.
British Journal of Haematology
Academic article
-
Seidel, Carina;
Hjorth-Hansen, Henrik;
Bendz, Bjørn;
Børset, Magne;
Sandset, Per Morten;
Hansen, John-Bjarne.
(1999)
Hepatocyte growth factor in serum after injection of unfractionated and low molecular weight heparin in healthy individuals.
British Journal of Haematology
Academic article
-
Hjorth-Hansen, Henrik;
Seifert, Mark F.;
Børset, Magne;
Aarset, Harald;
Østlie, Agnes;
Sundan, Anders.
(1999)
Marked Osteoblastopenia and Reduced Bone Formation in a Model of Multiple Myeloma Bone Disease in Severe Combined Immunodeficiency Mice.
Journal of Bone and Mineral Research
Academic article
-
Hjort-Hansen, Henrik;
Seidel, Carina;
Lamvik, Jon;
Børset, Magne;
Sundan, A.;
Waage, Anders.
(1999)
Elevated serum concentrations of hepatocyte growth factor in acute myelocytic leukaemia.
European Journal of Haematology
Academic article
-
Hjertner, ¯yvind;
Lyngaas Torgersen, Maria;
Seidel, Carina;
Hjorth-Hansen, Henrik;
Waage, Anders;
Børset, Magne.
(1999)
Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: A possible role for HGF in myeloma-associated osteolytic bone disease.
Blood
Academic article
-
Børset, Magne;
Seidel, Carina;
Hjorth-Hansen, Henrik;
Waage, Anders;
Sundan, Anders.
(1999)
The role of hepatocyte growth factor and its receptor C-Met in multiple myeloma and other blood malignancies.
Leukemia and Lymphoma
Academic article
1998
-
Seidel, C;
Børset, M;
Hjort-Hansen, Henrik;
Sundan, A;
Waage, Anders.
(1998)
Role of hepatocyte growth factor and its receptor c-met in multiple myeloma.
Medical Oncology (MO)
Academic article
1996
-
Børset, Magne;
Hjorth-Hansen, Henrik;
Seidel, Carina;
Sundan, Anders;
Waage, Anders.
(1996)
Hepatocyte growth factor and its receptor c-MET in multiple myeloma.
Blood
Academic article
Journal publications
-
Nygrén, Petra;
Bouhlal, Jonas;
Jokinen, Emmi;
Forstén, Sofia;
Laajala, Essi;
Dias, Diogo.
(2025)
High-throughput drug screening identifies SMAC mimetics as enhancers of NK-cell cytotoxicity in chronic myeloid leukemia.
Blood
Academic article
-
Flygt, Hjalmar;
Söderlund, Stina;
Richter, Johan;
Saussele, Susanne;
Koskenvesa, Perttu;
Stenke, Leif.
(2024)
Correction to: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial (Leukemia, (2024), 10.1038/s41375-024-02145-6).
Leukemia
Errata
-
Warfvinge, Rebecca;
Geironson Ulfsson, Linda;
Dhapola, Parashar;
Safi, Fatemeh;
Sommarin, Mikael;
Soneji, Shamit.
(2024)
Single-cell multiomics analysis of chronic myeloid leukemia links cellular heterogeneity to therapy response.
eLIFE
Academic article
-
Mahon, Francois-Xavier;
Pfirrmann, Markus;
Dulucq, Stéphanie;
Hochhaus, Andreas;
Panayiotidis, Panayiotis;
Almeida, Antonio.
(2024)
European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission.
Journal of Clinical Oncology
Academic article
-
Gambacorti-Passerini, Carlo;
Brümmendorf, Tim H.;
Abruzzese, Elisabetta;
Kelly, Kevin R.;
Oehler, Vivian G.;
García-Gutiérrez, Valentín.
(2024)
Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trial.
Leukemia
Academic article
-
Efficace, Fabio;
Mahon, Francois-Xavier;
Richter, Johan;
Piciocchi, Alfonso;
Cipriani, Marta;
Nicolini, Franck E..
(2024)
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial.
Leukemia
Academic article
-
Flygt, Hjalmar;
Söderlund, Stina;
Richter, Johan;
Saussele, Susanne;
Koskenvesa, Perttu;
Stenke, Leif.
(2024)
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial.
Leukemia
Academic article
-
Machova Polakova, Katerina;
Albeer, Ali;
Polivkova, Vaclava;
Krutska, Monika;
Vlcanova, Katerina;
Curik, Nikola.
(2023)
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib.
Leukemia
Academic article
-
Huuhtanen, Jani;
Adnan-Awad, Shady;
Theodoropoulos, Jason;
Forstén, Sofia;
Warfvinge, Rebecca;
Dufva, Olli.
(2023)
Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation.
Leukemia
Academic article
-
Geelen, Inge G.P.;
Gullaksen, Stein-Erik;
Ilander, Mette M.;
Olssen-Strömberg, Ulla;
Mustjoki, Satu;
Richter, Johan.
(2023)
Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects.
Annals of Hematology
Academic article
-
Behsen, Alenka Djarmila;
Vandsemb, Esten Nymoen;
Slørdahl, Tobias Schmidt;
Hjorth-Hansen, Henrik;
Quist-Paulsen, Petter;
Misund, Kristine.
(2023)
A patient with minimal myeloma treatment who survived for 20 years.
Haematologica
Academic article
-
Huuhtanen, Jani;
Ilander, Mette;
Yadav, Bhagwan;
Dufva, Olli M.J.;
Lähteenmäki, Hanna;
Kasanen, Tiina.
(2022)
IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia.
Journal of Clinical Investigation
Academic article
-
Flygt, Hjalmar;
Söderlund, Stina;
Stentoft, Jesper;
Richter, Johan;
Koskenvesa, Perttu;
Mustjoki, Satu.
(2021)
Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study.
European Journal of Haematology
Academic article
-
Richter, Johan;
Lübking, Anna;
Söderlund, Stina;
Lotfi, Kourosh;
Markevärn, Berit;
Själander, Anders.
(2021)
Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR—final report from AFTER-SKI.
Leukemia
Academic article
-
Hochhaus, Andreas;
Baccarani, Michele;
Silver, Richard T.;
Schiffer, Charles A.;
Apperley, Jane F.;
Cervantes, Francisco.
(2020)
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.
Leukemia
Academic literature review
-
Söderlund, Stina;
Persson, Inger;
Ilander, Mette;
Guilhot, Joelle;
Hjorth-Hansen, Henrik;
Koskenvesa, Perttu.
(2020)
Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy.
Leukemia Research
Academic article
-
Berentsen, Sigbjørn;
Barcellini, Wilma;
D'Sa, Shirley;
Randen, Ulla;
Tvedt, Tor Henrik Anderson;
Fattizzo, Bruno.
(2020)
Cold agglutinin disease revisited: a multinational, observational study of 232 patients.
Blood
Academic article
-
Rio-Machin, Ana;
Villiamy, Tom;
Hug, Nele;
Walne, Amanda;
Tawana, Kiran;
Cardoso, Shirleny.
(2020)
The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants.
Nature Communications
Academic article
-
Kreutzman, Anna;
Yadav, Bhagwan;
Brümmendorf, Tim H.;
Gjertsen, Bjørn Tore;
Lee, Moon Hee;
Janssen, Jeroen.
(2019)
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line.
Oncoimmunology
Academic article
-
Hjorth-Hansen, Henrik.
(2019)
TKI safety.
HemaSphere
Academic article
-
Bouillon, Anne-Sophie;
Ventura Ferreira, Monica S.;
Awad, Shady Adnan;
Richter, Johan;
Hochhaus, Andreas;
Kunzmann, Volker.
(2018)
Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemia.
Blood Advances
Academic article
-
Landberg, Niklas;
von Palffy, Sophia;
Askmyr, Maria K.;
Lilljebjorn, Henrik;
Sanden, Carl;
Rissler, Marianne.
(2018)
CD36 Defines Primitive Chronic Myeloid Leukemia Cells Less Responsive To Imatinib But Vulnerable To Antibody-Based Therapeutic Targeting.
Haematologica
Academic article
-
Saussele, Susanne;
Richter, Johan;
Guilhot, Joelle;
Gruber, Franz;
Hjorth-Hansen, Henrik;
Almeida, Antonio.
(2018)
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
The Lancet Oncology
Academic article
-
Pietarinen, Paavo O;
Eide, Christopher A;
Ayuda-Duran, Maria del Pilar;
Potdar, Swapnil;
Kuusanmäki, Heikki;
Andersson, Emma I.
(2017)
Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
OncoTarget
Academic article
-
Gullaksen, Stein-Erik;
Skavland, Jørn;
Gavasso, Sonia;
Tosevski, Vinko;
Warzocha, Krzysztof;
Dumrese, Claudia.
(2017)
Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib.
Haematologica
Academic article
-
Ilander, Mette;
Olsson-Strömberg, Ulla;
Schlums, Heinrich;
Guilhot, Joëlle;
Brück, Oscar;
Lähteenmäki, Hanna.
(2017)
Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.
Leukemia
Academic article
-
Hochhaus, Andreas;
Saussele, Susanne;
Rosti, Gianantonio;
Mahon, François-Xavier;
Janssen, Jeroen J.W.M.;
Hjorth-Hansen, Henrik.
(2017)
Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Annals of Oncology
Academic article
-
Warfvinge, Rebecca;
Geironson, Linda;
Sommarin, Mikael NE;
Lang, Stefan;
Karlsson, Christine;
Roschupkina, Teona.
(2017)
Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML.
Blood
Academic article
-
Rajala, Hanna L.M.;
El Missiry, Mohamed;
Ruusila, Anniina;
Koskenvesa, Perttu;
Brümmendorf, Tim H.;
Gjertsen, Bjørn Tore.
(2017)
Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia.
Journal of Cancer Research and Clinical Oncology
Academic article
-
Müller, Martin C.;
Cervantes, Francisco;
Hjorth-Hansen, Henrik;
Janssen, Jeroen J.W.M.;
Milojkovic, Dragana;
Rea, Delphine.
(2017)
Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel.
Critical Reviews in Oncology/Hematology
Academic literature review
-
El Missiry, Mohamed;
Hjorth-Hansen, Henrik;
Richter, Johan;
Olson-Strömberg, Ulla;
Stenke, Leif;
Porkka, Kimmo.
(2017)
Early BCR-ABL1 transcript decline after 1 month of tyrosine kinase inhibitor therapy as an indicator for treatment response in chronic myeloid leukemia.
PLOS ONE
Academic article
-
Hjorth-Hansen, Henrik;
Stentoft, Jesper;
Richter, Johan;
Koskenvesa, Perttu;
Höglund, Martin;
Dreimane, Arta.
(2016)
Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients.
Leukemia
Academic article
-
Landberg, Niklas;
Hansen, Nils Jakob Vest;
Askmyr, Maria K.;
Ågerstam, Helena;
Lassen, Carin F.;
Rissler, Marianne.
(2016)
IL1RAP expression as a measure of leukemic stem cell burden at diagnosis of chronic myeloid leukemia predicts therapy outcome.
Leukemia
Letter to the editor
-
El Missiry, Mohamed;
Adnan Awad, Shady;
Rajala, Hanna L.;
Al-Samadi, Ahmed;
Ekblom, Marja;
Markevän, Berit.
(2016)
Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia.
Journal of Cancer Research and Clinical Oncology
Academic article
-
Stray-Pedersen, Asbjørg;
Sorte, Hanne Sørmo;
Samarakoon, Pubudu Saneth;
Gambin, Tomasz;
Chinn, Ivan K.;
Akdemir, Zeynep H.C..
(2016)
Primary immunodeficiency diseases: Genomic approaches delineate heterogeneous Mendelian disorders.
Journal of Allergy and Clinical Immunology
Academic article
-
Söderlund, Stina;
Christiansson, Lisa;
Persson, Inger;
Hjorth-Hansen, Henrik;
Richter, Johan;
Simonsson, Bengt.
(2016)
Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli.
Leukemia Research
Academic article
-
Christiansson, Lisa;
Söderlund, Stina;
Mangsbo, Sara;
Hjorth-Hansen, Henrik;
Höglund, Martin;
Markevärn, Berit.
(2015)
The tyrosine kinase inhibitors imatinib and dasatinib reduce myeloid suppressor cells and release effector lymphocyte responses.
Molecular Cancer Therapeutics
Academic literature review
-
Espinosa, Aurora;
Hjorth-Hansen, Henrik;
Aasly, Karin;
Teigum, Ingvild;
Sivertsen, Guro Hustad;
Seghatchian, Jerard.
(2015)
Implementation of a standardised method for the production of allogeneic serum eye drops from regular blood donors in a Norwegian University Hospital: Some methodological aspects and clinical considerations.
Transfusion and Apheresis Science
Academic literature review
-
Hjorth-Hansen, Henrik;
Stenke, Leif;
Söderlund, Stina;
Dreimane, Arta;
Ehrencrona, Hans;
Gedde-Dahl, Thobias.
(2015)
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: Clinical results from a randomised phase-2 study (NordCML006).
European Journal of Haematology
Academic article
-
Koskenvesa, P;
Kreutzman, Anna;
Rohon, P;
Pihlman, M;
Vakkila, Emmi;
Rasanen, Anu.
(2014)
Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response.
European Journal of Haematology
Academic article
-
Fossmark, Reidar;
Skarsvåg, Espen Christoffer;
Aarset, Harald;
Hjort-Hansen, Henrik;
Waldum, Helge.
(2013)
Symptomatic primary (Al) amyloidosis of the stomach and duodenum.
Case Reports in Gastrointestinal Medicine
Academic article
-
Skarsvåg, Espen Christoffer;
Hjort-Hansen, Henrik;
Fossmark, Reidar.
(2013)
Symptomatic primary (AL) amyloidosis in the stomach and duodenum.
BestPractice Gastroenterologi
Article in business/trade/industry journal
-
Baccarani, Michele;
Deininger, MW;
Rosti, Gianantonio;
Hochhaus, Andreas;
Soverini, Simona;
Apperley, J.F..
(2013)
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
Blood
Academic literature review
-
Hjort-Hansen, Henrik;
Abboud, Camille;
Abdel-Rahman, Fawzi;
Abruzzese, Elizabetta;
Aguayo, Alvaro;
Aljurf, Mahmoud Deeb Saeed.
(2013)
Price of drugs for chronic myeloid leukemia (CML), reflection of the unsustainable cancer drug prices: perspective of CML Experts.
Blood
Academic literature review
-
Mustjoki, Satu;
Richter, Johan;
Barbany, Gisela;
Ehrencrona, Hans;
Fioretos, Thoas;
Gedde-Dahl, Thobias.
(2013)
Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients.
Leukemia
Academic article
-
Jönsson, Sofia;
Hjorth-Hansen, Henrik;
Olsson, Bob;
Wadenvik, H;
Sundan, Anders;
Standal, Therese.
(2012)
Imatinib inhibits proliferation of human mesenchymal stem cells and promotes early but not late osteoblast differentiation in vitro.
Journal of Bone and Mineral Metabolism
Academic article
-
Gruber, Franz;
Lundan, Tuija;
Goll, Rasmus;
Silye, Aleksandra;
Mikkola, Ingvild;
Rekvig, Ole Petter.
(2012)
BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations?.
Medical Oncology (MO)
Academic article
-
Kreutzman, Anna;
Jaatinen, Taina;
Greco, D;
Vakkila, Emmi;
Richter, J;
Ekblom, Marja.
(2012)
Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia.
Experimental Hematology
Academic article
-
Simonsson, B;
Gedde-Dahl, Tobias;
Markevärn, B;
Remes, Kari;
Stentoft, Jesper;
Almqvist, Anders.
(2011)
Combination of pegylated IFN-alpha 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia.
Blood
Academic article
-
Simonsson, B;
Hjorth-Hansen, Henrik;
Bjerrum, Ole W;
Porkka, K.
(2011)
Interferon alpha for Treatment of Chronic Myeloid Leukemia.
Current Drug Targets
Academic literature review
-
Koskela, Hanna;
Strømberg, Anniina;
Richter, Johan;
Hjorth-Hansen, Henrik;
Porkka, Kimmo;
Mustjoki, Satu.
(2011)
Tyrosine Kinase Inhibitor Therapy Induced Changes in Humoral Immunity in Patients with Chronic Myeloid Leukemia.
Blood
Abstract
-
Jönsson, S;
Hjorth-Hansen, Henrik;
Olsson, B;
Wadenvik, H;
Sundan, Anders;
Standal, Therese.
(2010)
Second-generation TKI dasatinib inhibits proliferation of mesenchymal stem cells and osteoblast differentiation in vitro.
Leukemia
Reader opinion piece
-
Gimsing, Peter;
Carlson, Kristina;
Turesson, Ingemar;
Fayers, Peter;
Waage, Anders;
Vangsted, Annette.
(2010)
Effect of pamidronate 30mg versus 90mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial.
The Lancet Oncology
Academic article
-
Berentsen, Sigbjørn;
Randen, Ulla;
Vågan, Anna Marita;
Hjort-Hansen, Henrik;
Vik, Anders;
Dalgaard, Jakob.
(2010)
High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease.
Blood
Academic article
-
Simonsson, Bengt;
Gedde-Dahl, Thobias;
Markevärn, Berit;
Remes, Kari;
Stentoft, Jesper;
Almqvist, Anders.
(2010)
MAJOR MOLECULAR RESPONSE RATE AT ONE YEAR IS HIGHER IF PEGYLATED INTERFERON ALPHA-2B IS ADDED TO IMATINIB IN NON-HR CHRONIC MYELOID LEUKEMIA PATIENTS IN IMATINIB INDUCED COMPLETE HEMATOLOGICAL REMISSION.
Haematologica
Abstract
-
Reseland, Janne Elin;
Reppe, Sjur;
Olstad, Ole Kristoffer;
Hjorth-Hansen, Henrik;
Brenne, Anne-Tove;
Syversen, Unni.
(2009)
Abnormal adipokine levels and leptin-induced changes in gene expression profiles in multiple myeloma.
European Journal of Haematology
Academic article
-
Mustjoki, Satu;
Ekblom, M;
Arstila, TP;
Dybedal, I;
Epling-Burnette, PK;
Guilhot, F.
(2009)
Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy.
Leukemia
Academic article
-
Baccarani, Michele;
Rosti, Gianantonio;
Castagnetti, Fausto;
Haznedaroglu, Ibrahim;
Porkka, Kimmo;
Abruzzese, Elisabetta.
(2009)
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study.
Blood
Academic article
-
Vefring, HK;
Gruber, Franz;
Wee, L;
Hovland, R;
Hjorth-Hansen, H;
Dahl, TG.
(2009)
Chronic Myelogenous Leukemia with the e6a2 BCR-ABL and Lacking Imatinib Response: Presentation of Two Cases.
Acta Haematologica
Academic article
-
Simonsson, Bengt;
Gedde-Dahl, Thobias;
Markevarn, B;
Remes, Kari;
Stentoft, J;
Almqvist, Anders.
(2009)
A Randomized Phase II Study Comparing Imatinib and the Combination of Imatinib and Pegylated Interferon Alpha-2b in Newly Diagnosed Non-High Risk Chronic Myeloid Leukemia (CML) Patients in Complete Hematological Remission After Imatinib Induction Therapy.
Blood
Abstract
-
Porkka, Kimmo;
Koskenvesa, Perttu;
Lundan, Tuija;
Rimpilaeinen, Johanna;
Mustjoki, Satu;
Smykla, Richard.
(2008)
Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia.
Blood
Academic article
-
Koskenvesa, P;
Rimpilainen, J;
Lundan, T;
Mustjoki, S;
Brethon, B;
Hjorth-Hansen, H.
(2007)
Dasatinib is an effective treatment of central nervous system Ph-positive leukemia.
Haematologica
Abstract
-
Gruber, Franz;
Hjorth-Hansen, H;
Mikkola, ingvild;
Stenke, L;
Johansen, Terje.
(2006)
A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib.
Leukemia
Reader opinion piece
-
Vanky, Eszter;
Hjorth-Hansen, Henrik;
Carlsen, Sven Magnus.
(2006)
Metformin and early pregnancy?.
Fertility and Sterility
Reader opinion piece
-
Vanky, Eszter;
Salvesen, Kjell Å;
Hjorth-Hansen, Henrik;
Bjerve, Kristian S;
Carlsen, Sven Magnus.
(2006)
Beneficial effect of metformin on pregnancy outcome in women with polycystic ovary syndrome is not associated with major changes in C-reactive protein levels or indices of coagulation.
Fertility and Sterility
Academic article
-
Berentsen, Sigbjørn;
Ulvestad, Tore Elling;
Ulvestad, Elling;
Langholm, Ruth;
Beiske, Klaus;
Hjorth-Hansen, Henrik.
(2006)
Primary chronic cold agglutinin disease: a population based clinical study of 86 patients.
Studies in Surface Science and Catalysis
Academic article
-
Rosti, Gianantonio;
Martinelli, G;
Castagnetti, F;
Testoni, N;
Specchia, G;
Bassan, R.
(2005)
Imatinib 800 mg: Preliminary results of a phase II trial of the GIMEMA CML working party in intermediate sokal risk patients and status-of-the-art of an ongoing multinational, prospective randomized trial of imatinib standard dose (400 mg daily) vs high dose (800 mg daily) in high sokal risk patients.
Blood
Abstract
-
Gruber, Franz;
Lamark, T;
Aanonli, T;
Sovershaev, MA;
Olsen, Marita;
Gedde-dahl, Tobias.
(2005)
Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL.
Leukemia
Academic article
-
Gruber, Franz;
Lamark, Trond;
Ånonli, Aileeen Cathrine;
Sovershaev, Mikhail;
Olsen, M;
Gedde-Dahl, T.
(2005)
Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL.
Leukemia
Academic article
-
Hov, Håkon;
Holt, Randi Utne;
Rø, Torstein Baade;
Fagerli, Unn-Merete;
Hjort-Hansen, Henrik;
Baykov, Vadim.
(2004)
A Selective c-Met Inhibitor Blocks an Autocrine Hepatocyte Growth Factor Growth Loop in ANBL-6 Cells and Prevents Migration and Adhesion of Myeloma cells.
Clinical Cancer Research
Academic article
-
Holt, Randi Utne;
Hjorth-Hansen, Henrik;
Waage, Anders;
Hjertner, ¯yvind;
Sundan, Anders;
Børset, Magne.
(2004)
Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells.
Oncogene
Academic article
-
Hov, Håkon;
Holt, Randi Utne;
Rø, Torstein;
Fagerli, Unn-merete;
Hjorth-Hansen, Henrik;
Baykov, Vadim.
(2004)
A selective c-Met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells.
Clinical Cancer Research
Academic article
-
Standal, T;
Hjort-Hansen, H;
Rasmussen, T;
Dahl, Inger Marie;
Lenhoff, S;
Brenne, AT.
(2004)
Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma.
Haematologica
Academic article
-
Berentsen, Sigbjørn;
Ulvestad, Elling;
Gjertsen, Bjørn tore;
Hjorth-Hansen, Henrik;
Langholm, Ruth;
Ghanima, Waleed.
(2004)
Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients.
Blood
Academic article
-
Berentsen, S;
Ulvestad, E;
Gjertsen, BT;
Hjort-Hansen, H;
Langholm, R;
Knutsen, H.
(2004)
Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients.
Blood
Academic article
-
Standal, T;
Hjorth-Hansen, Henrik;
Rasmussen, T;
Dahl, Inger Marie S.;
Lenhoff, Stig;
Brenne, Anne Tove.
(2004)
Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma.
Haematologica
Academic article
-
Brenne, Anne Tove;
Rø, Torstein Baade;
Waage, Anders;
Sundan, Anders;
Børset, Magne;
Hjorth-Hansen, Henrik.
(2002)
Interleukin-21 is a growth and survival factor for human myeloma cells.
Blood
Academic article
-
Hjorth-Hansen, Henrik.
(2001)
Sulter ut kreften med nye medisiner.
Dagbladet
Feature article
-
Seidel, Carina;
Hjertner, ¯yvind;
Abildgaard, Niels;
Heikendorff, Lene;
Hjorth, M.;
Westin, Jan.
(2001)
Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease.
Blood
Academic article
-
Hjertner, ¯yvind;
Hjorth-Hansen, Henrik;
Børset, Magne;
Seidel, Carina;
Waage, Anders;
Sundan, Anders.
(2001)
Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells.
Blood
Academic article
-
Hjertner, ¯yvind;
Qvigstad, Gunnar;
Hjorth-Hansen, Henrik;
Seidel, Carina;
Woodliff, Jeffery;
Epstein, Joshua.
(2000)
Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells.
British Journal of Haematology
Academic article
-
Seidel, Carina;
Børset, Magne;
Hjertner, ¯yvind;
Cao, Dianjun;
Abildgaard, Niels;
Hjorth-Hansen, Henrik.
(2000)
High levels of soluble syndecan-1 in myeloma-derived bone marrow : modulation of hepatocyte growth factor activity.
Blood
Academic article
-
Hjorth-Hansen, Henrik;
Seidel, Carina;
Lamvik, Jon;
Børset, Magne;
Sundan, Anders;
Waage, Anders.
(1999)
Elevated serum concentrations of hepatocyte growth factor in acute myelocytic leukaemia.
European Journal of Haematology
Academic article
-
Børset, Magne;
Hjort-Hansen, Henrik;
Johnsen, Ann-Charlotte;
Seidel, Carina;
Waage, Anders;
Espevik, Terje.
(1999)
Apoptosis, proliferation and NF-k(kappa)B activation induced by agonistic Fas antibodies in the human myeloma cell line OH-2: amplification of Fas-mediated apoptosis by tumor necrosis factor.
European Journal of Haematology
Academic article
-
Hjertner, ¯yvind;
Torgersen, Maria Lyngaas;
Seidel, Carina;
Hjort-Hansen, Henrik;
Waage, Anders;
Børset, Magne.
(1999)
Hepatocyte Growth Factor (HGF) Induces Interleukin-11 Sedretion From Osteoblasts: A Possible Role for HGF in Myeloma-Associated Osteolytic Bone Disease.
Blood
Academic article
-
Børset, Magne;
Seidel, Carina;
Hjorth-Hansen, Henrik;
Waage, Anders;
Sundan, Anders.
(1999)
The Role of Hepatocyte Growth Factor and its Receptor C-Met in Multiple Myeloma and Other Blood Malignancies.
Leukemia and Lymphoma
Academic article
-
Hjort-Hansen, Henrik;
Waage, Anders;
Børset, M..
(1999)
Interleukin-15 blocks apoptosis and induces proliferation of the human myeloma cell line OH-2 and freshly isolated myeloma cells.
British Journal of Haematology
Academic article
-
Seidel, Carina;
Hjorth-Hansen, Henrik;
Bendz, Bjørn;
Børset, Magne;
Sandset, Per Morten;
Hansen, John-Bjarne.
(1999)
Hepatocyte growth factor in serum after injection of unfractionated and low molecular weight heparin in healthy individuals.
British Journal of Haematology
Academic article
-
Hjorth-Hansen, Henrik;
Seifert, Mark F.;
Børset, Magne;
Aarset, Harald;
Østlie, Agnes;
Sundan, Anders.
(1999)
Marked Osteoblastopenia and Reduced Bone Formation in a Model of Multiple Myeloma Bone Disease in Severe Combined Immunodeficiency Mice.
Journal of Bone and Mineral Research
Academic article
-
Hjort-Hansen, Henrik;
Seidel, Carina;
Lamvik, Jon;
Børset, Magne;
Sundan, A.;
Waage, Anders.
(1999)
Elevated serum concentrations of hepatocyte growth factor in acute myelocytic leukaemia.
European Journal of Haematology
Academic article
-
Hjertner, ¯yvind;
Lyngaas Torgersen, Maria;
Seidel, Carina;
Hjorth-Hansen, Henrik;
Waage, Anders;
Børset, Magne.
(1999)
Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: A possible role for HGF in myeloma-associated osteolytic bone disease.
Blood
Academic article
-
Børset, Magne;
Seidel, Carina;
Hjorth-Hansen, Henrik;
Waage, Anders;
Sundan, Anders.
(1999)
The role of hepatocyte growth factor and its receptor C-Met in multiple myeloma and other blood malignancies.
Leukemia and Lymphoma
Academic article
-
Seidel, C;
Børset, M;
Hjort-Hansen, Henrik;
Sundan, A;
Waage, Anders.
(1998)
Role of hepatocyte growth factor and its receptor c-met in multiple myeloma.
Medical Oncology (MO)
Academic article
-
Børset, Magne;
Hjorth-Hansen, Henrik;
Seidel, Carina;
Sundan, Anders;
Waage, Anders.
(1996)
Hepatocyte growth factor and its receptor c-MET in multiple myeloma.
Blood
Academic article
Report
-
Hjorth-Hansen, Henrik;
Gruber, Franz.
(2009)
Towards a quantitative understanding of CML resistance – selective and de-selective processes upon treatment with tyrosine kinase inhibitors and their clinical interpretation.
Franz Gruber selv
Doctoral dissertation
-
Hjorth-Hansen, Henrik;
Gruber, Franz;
Gedde-dahl, Tobias.
(2004)
Nasjonalt handlingsprogram for kronisk myelogen leukemi.
Norsk selskap for hematologi
Report
-
Hjorth-Hansen, Henrik.
(2001)
Novel cytokines in growth control and bone disease of multiple myeloma.
NTNU Trykk
Doctoral dissertation
Outreach
2016
-
Academic lectureHjorth-Hansen, Henrik. (2016) Pegylated IFN use in CML-a Nordic perspective. Professor Phillippe Rousselot EICML , Versailles 2016-05-13 - 2016-05-16
-
LectureHjorth-Hansen, Henrik. (2016) How to design new studies in CML. Nordic CML Study group Nordic CML Education Symposium , Malmö 2016-04-27 - 2016-04-28
-
Academic lectureHjorth-Hansen, Henrik. (2016) Pegylated IFN in CML. AOP Pharma 9th International Hematology Expert Meeting , Nice 2016-04-29 - 2016-05-01
-
Academic lectureHjorth-Hansen, Henrik. (2016) Safety and Efficacy of Combination of Pegylated Interferonalpha2b to Standard Dose Dasatinib in Newly Diagnosed CP CML . Nordic CML Study Group Nordic CML Education Symposium , Malmö 2016-04-27 - 2016-04-28
2015
-
LectureHjorth-Hansen, Henrik. (2015) Myeloid malignancies as models of oncogenesis - molecular characterization. Oslo Cancer Cluster Cancer Crosslinks , Oslo 2015-01-15 - 2015-01-15
-
Academic lectureHjorth-Hansen, Henrik; Janssen, Jeroen. (2015) CML patients resistant due to mutations. Ariad Ariad education symposium EHA 2015 , Wien 2015-06-10 - 2015-06-10
-
Academic lectureHjorth-Hansen, Henrik; Richter, Johan; Gedde-dahl, Tobias; Gjertsen, Bjørn tore; Gruber, Franz; Stenke, Leif. (2015) Safety and Efficacy of Addition of Pegylated Interferon alpha2b to Standard Dose Dasatinib in Newly Diagnosed Chronic Phase CML Patients. American Society of Hematology ASH 57th annual meeting , Orlando, FL 2015-12-04 - 2015-12-08
2011
-
Academic lectureHjorth-Hansen, Henrik. (2011) NordCML006- study update. Prof Jiri Mayer European Investigators in CML , Praha 2011-05-05 - 2011-05-07
-
Academic lectureHjorth-Hansen, Henrik. (2011) Plans and problems- NordCML007 and NordCML009. Nordic CML Study Group v/ Henrik Hjorth-hansen Nordic CML Study Group Autumn meeting , Stockholm 2011-11-09 - 2011-11-09
-
Academic lectureHjorth-Hansen, Henrik. (2011) Update of NordCML006. Nordic CML Study Group v/ Henrik Hjorth-hansen Nordic CML Study Group Autumn meeting , Stockholm 2011-11-09 - 2011-11-09
-
Academic lectureHjorth-Hansen, Henrik. (2011) CML therapy – an overview. Nordic society of hematology Nordisk hematologisk Vårmøte , Bergen 2011-05-03 - 2011-05-05
-
Academic lectureHjorth-Hansen, Henrik. (2011) Results from NordCML006. Nordic CML Study Group Nordic CML Symposium , Stockholm 2011-11-10 - 2011-11-10
-
Academic lectureHjorth-Hansen, Henrik. (2011) Nordic CML studies: Update and plans. European Leukemia net European Leukemia Net CML meeting , Mannheim 2011-07-01 - 2011-07-03
-
Academic lectureHjorth-Hansen, Henrik. (2011) Update NordCML006. Nordic CML Study Group v/ Henrik Hjorth-hansen Nordic CML Study Group Spring meeting , Stockholm 2011-03-23 - 2011-03-23
-
Academic lectureHjorth-Hansen, Henrik. (2011) KML-behandling: Fortid-nåtid-fremtid. Dansk myeloid studiegruppe v Ole Weis Bjerrum Dansk myeloid studiegruppe , Odense 2011-10-26 - 2011-10-26
2010
-
Academic lectureHjorth-Hansen, Henrik. (2010) Treatment Resistance: Overview. Oslo Cancer Cluster Cancer Crosslinks , Oslo 2010-01-14 - 2010-01-14
2009
-
Academic lectureHjorth-Hansen, Henrik. (2009) NordCML006 A randomized phase II study of dasatinib and imatinib treatment in newly Diagnosed CML focusing on disease burden in stem cells. European Leukemia Net European Leukemia Net 6th Annual meeting , Mannheim 2009-02-02 - 2009-02-04
-
Academic lectureHjorth-Hansen, Henrik. (2009) Start meeting for Nordic CML Study Group study NordCML006. Extensive tasks as meeting leader, presenter and coordinator. Nordic CML Study Group Start meeting for Nordic CML Study Group study NordCML006. , Arlanda 2009-02-11 - 2009-02-11
-
Academic lectureHjorth-Hansen, Henrik. (2009) The future role of new tyrosine kinase inhibitors in CML. Nordic CML Study Group Nordic CML Symposium , Arlanda 2009-10-22 - 2009-10-22
-
Academic lectureHjorth-Hansen, Henrik. (2009) CML in 2009; Cure with drug therapy in sight?. Nordic Hematology Society Nordic Hematology Spring Meeting , Tammerfors 2009-05-06 - 2009-05-08
-
Academic lectureHjorth-Hansen, Henrik. (2009) Why should clinical trials be prioiritized? Round table discussion. Oslo Cancer Cluster Cancer Crosslinks , Oslo 2009-01-15 - 2009-01-15
-
Academic lectureHjorth-Hansen, Henrik. (2009) Information om NordCML006. Svenska KML-gruppen Möte i svenska KML-gruppen (Svenska hematologiföreningen) , Arlanda 2009-03-18 - 2009-03-18
-
Academic lectureHjorth-Hansen, Henrik. (2009) Behandling av pasienter med ileofemoral trombose. Karkirurgisk avdeling St Olavs Regionmøte i karkirurgi , Trondheim 2009-11-27 - 2009-11-28
2008
-
Academic lectureHjorth-Hansen, Henrik. (2008) Stor reviewjobb med lesing av 150 abstracts i kategorien Klinisk KML på American Society of Hematology. Deretter Moderator for oral session på samme møtet. American Society of Hematology 50. Årsmøte , San Fransisco 2008-12-05 - 2008-12-08
-
Academic lectureMustjoki, Satu; Ekblom, Marja; Arstila, T Petteri; Dybedal, Ingunn; Hjorth-Hansen, Henrik; Stenke, Leif. (2008) Clonal Expansion of T/NK-Cells during Tyrosine Kinase Inhibitor Dasatinib Therapy. American Society of Hematology 50. Årsmøte American Society of Hematology , San Fransisco 2008-12-05 - 2008-12-09
-
Academic lectureBaccarani, Michele; Castagnetti, Fausto; Simonsson, Bengt; Porkka, K; Haznedaroglu, Ibrahim; Hjorth-Hansen, Henrik. (2008) Cytogenetic and Molecular Response to Imatinib in High Risk (Sokal) Chronic Myeloid Leukemia (CML): Results of An European Leukemianet Prospective Study Comparing 400 Mg and 800 Mg Front-Line. American Soc of Hematology 50. Årsmøte American Soc of Hematology , San Fransisco 2008-12-05 - 2008-12-08
2007
-
Academic lectureHjorth-Hansen, Henrik. (2007) Kliniske studier med Sprycel (dasatinib). Bristol-Myers Squibb Introduksjonsmøte Sprycel , Gardermoen 2007-03-15 - 2007-03-15
-
Academic lectureBaccarani, Michele; Castagnetti, Fausto; Porkka, K; Lanng Nielsen, Johan; Hjorth-Hansen, Henrik; Haznedaroglu, Ibrahim. (2007) A Prospective Study of Imatinib 400 mg vs 800 mg Frontline in High Risk Ph+ Chronic Myeloid Leukemia (CML) Patients. American Society of Hematology American Society of Hematologys årsmøte , Atlandta, GA 2007-12-06 - 2007-12-11
-
Academic lectureHjorth-Hansen, Henrik. (2007) CML stem cell targeting: Early clinical experience with BMS- 354825. Nordic CML Study Group Nordic CML symposium , Uppsala 2007-10-23 - 2007-10-24
-
Academic lectureHjorth-Hansen, Henrik. (2007) Long term BM aplasia after tyrosine kinase inhibitor therapy. Nordic CML Study Group Nordic CML Study Group Spring Workshop , Trondheim 2007-05-02 - 2007-05-03
-
Academic lectureHjorth-Hansen, Henrik. (2007) Nye KML-studier. St Olavs Hospital Regionmøte i hematologi og lymfom , Trondheim 2007-10-18 - 2007-10-19
-
Academic lectureHjorth-Hansen, Henrik. (2007) Long term bone marrow aplasia induced by tyrosine kinase inhibitor therapy. European Investigators in Chronic Myeloid Leukemia European Investigators in Chronic Myeloid Leukemia Annual meeting , Stockholm 2007-05-10 - 2007-05-12
-
PosterLundan, Tuija; Gruber, Franz X.E.; Silye, Aleksandra; Hjorth-Hansen, Henrik; Mikkola, I; Remes, Kari. (2007) The Mutation Spectrum of CML Patients Resistant to Imatinib: More Heterogeneous Than Just BCR-ABL Kinase Domain Point Mutations?. American Society of Hematology American Society of Hematology årsmøte , Atlanta, Georgia, USA 2007-12-06 - 2007-12-11
-
PosterMustjoki, S; Laurinolli, Tuisko; Ekblom, Marja; Rauhala, Auvo; Sinisalo, Marjatta; Almqvist, Anders. (2007) Clonal Large Granular Lymphocyte (LGL) Expansion Associated with Dasatinib Therapy. American Society of Hematology American Society of Hematologys årsmøte , Atlanta, GA 2007-12-06 - 2007-12-11
2006
-
Academic lectureHjorth-Hansen, Henrik. (2006) Oppdatering om KML og studier. Norsk selskap for hematologi Vintermøte , Lillehammer 2006-03-07 - 2006-03-08
-
Academic lectureHjorth-Hansen, Henrik. (2006) Treatment of multiple myeloma – is it really changing?. NTNU Polish-Norwegian Seminar: Multiple Myeloma - From Basic Research to the Clinic , Trondheim 2006-10-17 - 2006-10-17
-
Academic lectureHjorth-Hansen, Henrik. (2006) Report from Nordic Chronic Myelogenous Leukemia Study Group (NCMLSG). Swedish Society of hematology Nordic Hematology Annual Spring Meeting , Gothenburg 2006-05-11 - 2006-05-13
2005
-
Academic lectureHjorth-Hansen, Henrik; Gruber, Franz. (2005) Mutation analysis in chronic myelogenous leukemia and how to proceed. Nordic CML Study Group Nordic CML symposium , København 2005-09-29 - 2005-09-29
-
Academic lectureHjorth-Hansen, Henrik; Gruber, Franz. (2005) Mutational analysis in CML -How to proceed. Nordic CML StudyGrouop 2005-09-29 -
-
Academic lectureHjorth-Hansen, Henrik. (2005) Oppdatering om KML. Norsk hematologisk selskaps Norsk hematologisk selskaps vintermøte , Lillehammer 2005-03-10 - 2005-03-11
-
PosterGruber, Franz; Hjorth-Hansen, Henrik; Et, Al. (2005) Quantitative Analyses of BCR-ABL Mutations Associated with Imatinib Treatment in CML. American Society of Hematology American Society of Hematology Annual meeting , Atlanta Georgia 2005-12-08 - 2005-12-13
-
PosterRosti, Gianantonio; Hjorth-Hansen, Henrik. (2005) Imatinib 800 mg: Preliminary Results of a Phase II Trial of the GIMEMA CML Working Party in Intermediate Sokal Risk Patients and Status-of-the-Art of an Ongoing Multinational, Prospective Randomized Trial of Imatinib Standard Dose (400 mg Daily) vs High Dose (800 mg Daily) in High Sokal Risk Patients. American Society of Hematology American Society of Hematology Annual Meeting , Atlanta, Geargia 2005-12-08 - 2005-12-13
2004
-
Academic lectureHjorth-Hansen, Henrik. (2004) Oppdatering av kliniske studier i KML. Norsk selskap for hematologi Vintermøte-Norsk selskap for hematologi , Lillehammer 2004-03-25 - 2004-03-26
-
PosterBørset, Magne; Hov, Håkon; Holt, Randi Utne; Rø, Torstein Baade; Fagerli, Unn-merete; Hjorth-Hansen, Henrik. (2004) A selective inhibitor of c-Met blocks an autocrine HGF growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells. The American Society of Hematology The American Society of Hematology 46th Annual Meeting , San Diego, CA 2004-12-04 - 2004-12-07
2003
-
PosterStandal, Therese; Hjorth-Hansen, Henrik; Dahl, Ivar M.; Brenne, Anne Tove; Waage, Anders; Børset, Magne. (2003) Elevated plasma OPN in multiple myeloma patients. Multiple Myeloma 9th International Workshop , Salamanca, Spania 2003-05-27 -
-
PosterHov, Håkon; Fagerli, Unn-Merete; Holt, Randi Utne; Rø, Torstein Baade; Hjorth-Hansen, Henrik; Waage, Anders. (2003) Tyrosine kinases: novel targets in cancer treatment. PhysPharm 2003, Scandinavian Congress of Physiology and Pharmacology, , Odensen, Danmark 2003-10-14 -
2002
-
Academic lectureRø, Torstein Baade; Brenne, Anne Tove; Hjertner, ¯yvind; Hjorth-Hansen, Henrik; Sundan, Anders; Waage, Anders. (2002) Bone morphogenetic protein-5, -6 and -7 inhibit proliferation and induce apoptosis in four human myeloma cell lines. 18th UICC International Cancer Congress , Oslo, Norway 2002-07-05 -
-
Academic lectureRø, Torstein Baade; Holt, Randi Utne; Brenne, Anne Tove; Waage, Anders; Hjorth-Hansen, Henrik; Hjertner, ¯yvind. (2002) Bone Morphogenetic Protein (BMP) Family Members BMP-5, BMP-6 and BMP-7 Inhibit Proliferation and Induce Apoptosis in Human Myeloma cells. American Society of Hematology Forty-fourth annual meeting , Philadelphia, Pennsylvania 2002-12-10 -
-
PosterHjorth-Hansen, Henrik; Rø, Torstein Baade; Brenne, Anne Tove; Waage, Anders; Sundan, Anders; Børset, Magne. (2002) Interleukin-21 is a growth and survival factor for human myeloma cells. Nordisk forening for hematologis årmøte , Linkøping, Sverige 2002-06-01 -
2001
-
PosterSeidel, Carina; Hjertner, ¯yvind; Hjorth-Hansen, Henrik; Waage, Anders; Sundan, Anders; Børset, Magne. (2001) OPG levels are reduced in patients with myeloma and correlate with skeletal involvement. Mayo Clinic: The Judith & George Goldman Symposium on Innovative Research in Myeloma , The Ritz Carlton, Amelia Island, Florida, USA 2001-01-21 -
-
PosterBørset, Magne; Standahl, Therese; Hjertner, ¯yvind; Seidel, Carina; Hjorth-Hansen, Henrik; Waage, Anders. (2001) Binding, Internalization and Degradation of Osteoprotegerin in Human Myeloma Cells. American Society of Hematology 43rd Annual Meeting and Exposition , Orlando, Florida, USA 2001-12-11 -
-
PosterRø, Torstein Baade; Brenne, Anne Tove; Waage, Anders; Sundan, Anders; Børset, Magne; Hjorth-Hansen, Henrik. (2001) Interleukin-21 is a growth and survival factor for human myeloma cells. American Society of hematology 43rd Annual Meeting and Exposition , Orlando, USA 2001-12-11 -
-
Academic lectureRø, Torstein Baade; Brenne, Anne Tove; Waage, Anders; Sundan, Anders; Børset, Magne; Hjorth-Hansen, Henrik. (2001) Interleukin-21 is a growth and survival factor for human myeloma cells. The 43rd Annual Meeting of The American Society of Hematology , Orlando, Florida, USA 2001-12-11 -
2000
-
Popular scientific lectureHjertner, ¯yvind; Hjorth-Hansen, Henrik; Børset, Magne; Seidel, Carina; Waage, Anders; Sundan, Anders. (2000) Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells. American Society of Hematology, Forty-second annual meeting , San Francisco, CA, December 1-5, 2000
-
PosterHjertner, ¯yvind; Hjorth-Hansen, Henrik; Børset, Magne; Seidel, Carina; Waage, Anders; Sundan, Anders. (2000) Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells. American Society of Hematology, Forty-sescond annual Meeting , San Francisco, USA, December 1-5, 2000
1999
-
Popular scientific lectureHjorth-Hansen, Henrik. (1999) Cytokinenes rolle i osteoblastfysiologi relatert til myelom og beinmargsdestruksjon. Oppdalsmøtet , Oppdal 1999-07-01 -
-
Popular scientific lectureHjertner, ¯yvind; Hjorth-Hansen, Henrik; Woodliff, J.; Waage, Anders; Børset, Magne. (1999) Expression of urokinase plasminogen activator (uPA) and the uPA receptor (uPAR) in myeloma cells. American Society of Hematology, 41st Annual Meeting, , New Orleans, December 1999
-
Popular scientific lectureHjorth-Hansen, Henrik; Hjertner, ¯yvind; Seidel, Carina; Børset, Magne; Waage, Anders; Sundan, Anders. (1999) Bone morphogenetic protein (BMP)-4 induces apoptosis and inhibits proliferation in myeloma cells by inhibition of the interleukin (IL)-6 signalling pathway. American Society of Hematology 41st Annual Meeting , New Orleans, December 1999
-
Popular scientific lectureHjorth-Hansen, Henrik; Hjertner, ¯yvind; Børset, Magne; Sundan, Anders; Waage, Anders. (1999) Hepatocyte growth factor (HGF) induces interleukin (IL)-6 production in murine osteoblasts, bone marrow stroma and whole organ cultures of calvariae. American Society of Hematology 41st Annual Meeting , New Orleans, December 1999
-
Popular scientific lectureSundan, Anders; Hjertner, ¯yvind; Torgersen, M. Lyngaas; Seidel, Carina; Hjorth-Hansen, Henrik; Waage, Anders. (1999) HGF induces IL-11 secretion from osteoblasts : a possible role for HGFin myeloma-associated bone disease. VII International Multiple Myeloma Workshop , Stockholm, Sweden, September 1-5, 1999
1998
-
PosterHjorth-Hansen, Henrik. (1998) Interleukin 15 induces proliferation and prevents apoptosis in myeloma. American Society of Hematology, 40th Meeting , Miami, Florida, USA
-
PosterHjorth-Hansen, Henrik. (1998) An animal model of multiple myeloma bone disease in SCID mice. Norsk Biokjemisk Møte , Lillehammer
-
PosterHjertner, ¯yvind; Torgersen, Maria; Moen, Siv; Børset, Magne; Hjort-Hansen, Henrik; Waage, Anders. (1998) The Expression of hepatocyte growth factor (HGF) and FAS ligands (FAS L) in myeloma cell lines. Biokjemisk kontaktmøte , Lillehammer Hotell, Lillehammer
-
Popular scientific lectureHjorth-Hansen, Henrik. (1998) Modell for myelomatøs bensykdom i SCID mus. Nordisk Vårmøte i Hematologi , Stockholm, Sverige
-
Popular scientific lectureHjorth-Hansen, Henrik. (1998) Modell for myelomatøs bensykdom i SCID mus. Nordisk Forskningsseminar i Hematologi , Soria Moria, Oslo